

Tularaemia (Infectious Disease) - Drugs in Development, 2021

<https://marketpublishers.com/r/T1E485F813D4EN.html>

Date: September 2021

Pages: 44

Price: US\$ 2,000.00 (Single User License)

ID: T1E485F813D4EN

Abstracts

Tularaemia (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Drugs In Development, 2021, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape. Tularaemia is an infection caused due to a bacterium called *Francisella tularensis*. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II

and Preclinical stages are 1 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Tularaemia - Overview
- Tularaemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Tularaemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tularaemia - Companies Involved in Therapeutics Development
- Appili Therapeutics Inc
- Aradigm Corp (Inactive)
- DynPort Vaccine Company LLC
- Emergex Vaccines Holding Ltd
- EpiVax Inc
- Tularaemia - Drug Profiles
- ATI-1701 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- ciprofloxacin - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- NDBR-101 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- Small Molecules for Infectious Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress

SRI-011225 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tularaemia [strain B] vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tularaemia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tularaemia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tularemia vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tularaemia - Dormant Projects

Tularaemia - Discontinued Products

Tularaemia - Product Development Milestones

Featured News & Press Releases

Sep 15, 2021: MRIGlobal expert co-authors article examining effective methods for Elusive Tularemia Vaccine

Dec 29, 2020: VAXIL provides update on USAMRIID and oral experiments

Jan 28, 2020: Researchers present positive interim data on Appili Therapeutics' ATI-1701 Biodefense program at 2020 ASM Biothreats

Nov 18, 2019: Researchers present new positive interim data on Appili Therapeutics ATI-1701 biodefense program at 2019 Chemical and Biological Defense Science & Technology Conference

Aug 20, 2019: Researchers to present new data on ATI-1701 at the 2019 Military Health System Research Symposium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Tularaemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Tularaemia - Pipeline by Appili Therapeutics Inc, 2021
Tularaemia - Pipeline by Aradigm Corp (Inactive), 2021
Tularaemia - Pipeline by DynPort Vaccine Company LLC, 2021
Tularaemia - Pipeline by Emergex Vaccines Holding Ltd, 2021
Tularaemia - Pipeline by EpiVax Inc, 2021
Tularaemia - Dormant Projects, 2021
Tularaemia - Dormant Projects, 2021 (Contd..1)
Tularaemia - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tularaemia, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Tularaemia (Infectious Disease) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/T1E485F813D4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T1E485F813D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970